var data={"title":"Iron sucrose: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iron sucrose: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6404?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iron-sucrose-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iron sucrose: Patient drug information&quot;</a> and <a href=\"topic.htm?path=iron-sucrose-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iron sucrose: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184604\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Venofer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184605\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Venofer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184620\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184607\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Doses expressed in mg of <b>elemental</b> iron. <b>Note: </b>Test dose: Product labeling does not indicate need for a test dose in product-naive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Per National Kidney Foundation KDOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron-deficiency anemia in chronic kidney disease (CKD):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemodialysis-dependent patient:</i> 100 mg administered during consecutive dialysis sessions to a cumulative total dose of 1,000 mg (10 doses); may repeat treatment if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Peritoneal dialysis-dependent patient:</i> Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1,000 mg in 3 divided doses); may repeat treatment if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nondialysis-dependent patient:</i> 200 mg administered on 5 different occasions within a 14-day period (total cumulative dose: 1,000 mg in 14-day period); may repeat treatment if clinically indicated. <b>Note:</b> Dosage has also been administered as 2 infusions of 500 mg on day 1 and day 14 (limited experience).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-associated anemia (off-label use):</b> IV: 200 mg once every 3 weeks for 5 doses (Bastit 2008) or 100 mg once weekly during weeks 0 to 6, followed by 100 mg every other week from weeks 8 to 14 (Hedenus 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6010345\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=iron-sucrose-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iron sucrose: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Doses expressed in mg of <b>elemental</b> iron. <b>Note: </b>Test dose: Product labeling does not indicate need for a test dose in product-naive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Per National Kidney Foundation KDOQI Guidelines, initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Iron-deficiency anemia in chronic kidney disease (CKD): </b>Children &ge;2 years of age and Adolescents: IV: <b>Note:</b> Not indicated for iron replacement treatment in children and adolescents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemodialysis-dependent patient:</i> Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg/dose) every 2 weeks for 12 weeks (6 doses); may repeat if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nondialysis-dependent patient (concurrent erythropoietin therapy)</i>\n      <i>:</i> Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg/dose) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Peritoneal dialysis-dependent patient (concurrent erythropoietin therapy)</i>\n      <i>:</i> Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg/dose) every 4 weeks for 12 weeks (3 doses); may repeat if clinically indicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184608\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160034\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic kidney disease, nondialysis-dependent: No dosage adjustment necessary (indicated for use in nondialysis-dependent CKD patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: No dosage adjustment necessary (indicated for use in CKD patients on hemodialysis); not dialyzable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: No dosage adjustment necessary (indicated for use in CKD patients on peritoneal dialysis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160035\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184587\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venofer: 20 mg/mL (2.5 mL, 5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184573\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963477\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Strength of iron sucrose is expressed as elemental iron.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184590\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer intravenously as a slow IV injection (<b>not</b> for rapid IV injection) or as an IV infusion. Can be administered through dialysis line.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Slow IV injection: Administer undiluted over 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion: Infuse diluted solution over 5 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Slow IV injection: May administer doses &le;200 mg undiluted by slow IV injection over 2 to 5 minutes. When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session (generally within the first hour).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infusion: Infuse diluted doses &le;200 mg over at least 15 minutes; infuse diluted 300 mg dose over 1.5 hours; infuse diluted 400 mg dose over 2.5 hours; infuse diluted 500 mg dose over 3.5 to 4 hours (limited experience). When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184589\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Iron-deficiency anemia:</b> Treatment of iron-deficiency anemia in chronic kidney disease (CKD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474543\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chemotherapy-associated anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7897706\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iron sucrose may be confused with ferumoxytol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184579\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Events and incidences are associated with use in adults unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (2% to 3%; children: 2%; hemodialysis patients: 39%; may be related to total dose or rate of administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 13%; children: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 15%; children: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps (1% to 3%; hemodialysis patients: 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (2% to 16%), pharyngitis (2% to 16%), sinusitis (2% to 16%), upper respiratory tract infection (2% to 16%; children: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (7% to 8%; children: 2%), peripheral edema (3% to 7%), chest pain (1% to 6%), thrombosis (children: 2%; arteriovenous fistula), cardiac failure (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (1% to 7%; children: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (&le;4%), hypervolemia (1% to 3%), gout (&le;3%), hyperglycemia (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5% to 9%; children: 4%), diarrhea (5% to 8%), dysgeusia (&le;8%), peritonitis (children: 4%), abdominal pain (1% to 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft complications (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (&gt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&le;6%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (3% to 6%), arthralgia (1% to 4%), myalgia (&le;4%), weakness (1% to 3%), back pain (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (1% to 6%), cough (1% to 3%; children: 4%), nasal congestion (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 3%; children: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylactoid reaction, angioedema, bradycardia, bronchospasm, circulatory shock, confusion, facial rash, hyperhidrosis, hypersensitivity reaction (including wheezing), hypoesthesia, joint swelling, local discoloration (at injection site following extravasation), loss of consciousness, necrotizing enterocolitis (reported in premature infants; no causal relationship established), paresthesia, seizure, shock, urine discoloration, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184593\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to iron sucrose or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for iron is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184577\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Cases of hypersensitivity reactions, including anaphylactic and anaphylactoid reactions (some fatal), have been reported. Monitor patients during and for &ge;30 minutes postadministration; discontinue immediately for signs/symptoms of a hypersensitivity reaction (shock, hypotension, loss of consciousness) or if signs of intolerance occur. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Significant hypotension has been reported frequently in hemodialysis-dependent patients. Has also been reported in peritoneal dialysis and nondialysis patients. Hypotension may be related to total dose or rate of administration (avoid rapid IV injection), follow recommended guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Withhold iron in the presence of tissue iron overload; periodic monitoring of hemoglobin, hematocrit, serum ferritin, and transferrin saturation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299545\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184581\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9004&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184583\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184594\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Iron can be detected in the fetus and cord blood; concentrations may be influenced by maternal iron status (IOM 2001). iron-deficiency anemia in a pregnant female may be associated with adverse events, including low birth weight, preterm birth, or increased perinatal mortality (ACOG 95 2008; IOM 2001).</p>\n    <p style=\"text-indent:0em;\">Iron requirements increase during pregnancy. All females should be screened for iron deficiency during pregnancy; if iron-deficiency anemia is present, supplemental iron (in addition to prenatal vitamins) should be administered. Oral preparations are generally sufficient, however parenteral iron therapy may be used in females who cannot tolerate or will not take oral iron, in cases of severe iron deficiency, or when malabsorption is present (ACOG 95 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789329\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron is present in breast milk (IOM 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In one study, iron concentrations were not increased following a single infusion of iron sucrose 100 mg IV to 10 women (2 to 3 days postpartum) with iron-deficiency anemia; milk concentrations were evaluated for 4 days after the injection (Breymann 2007). Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants (IOM 2001). The manufacturer recommends caution be used if iron sucrose is administered to a breastfeeding female.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184585\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD patients: Hematocrit, hemoglobin, serum ferritin, serum iron, transferrin, percent transferrin saturation (TSAT), TIBC (takes ~4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC); iron status should be assessed &ge;48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and &ge;30 minutes following infusion); hypotension (during and following infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chemotherapy-associated anemia (off-label use): Iron, total iron-binding capacity, transferrin saturation, or ferritin levels at baseline and periodically (Rizzo, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184588\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Goals of therapy (adults): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ferritin and TSAT:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease (2006):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD patients on dialysis: Serum ferritin &gt;200 ng/mL and TSAT&gt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD patients not on dialysis or CKD patients on peritoneal dialysis: Serum ferritin &gt; 100 ng/mL and TSAT&gt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> There is insufficient evidence to support maintaining serum ferritin &gt; 500 ng/mL (KDOQI 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemoglobin:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of the Hemoglobin Target: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD patients (dialysis and non-dialysis patients) receiving ESA therapy: Hemoglobin target should generally be in the range of 11 to 12 g/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>The hemoglobin target should <i>not </i>be &gt;13 g/dL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184576\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. The released iron increases serum iron concentrations and is incorporated into hemoglobin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184592\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Healthy adults: 7.9 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Dissociated into iron and sucrose by the reticuloendothelial system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Healthy adults: 6 hours; Nondialysis-dependent adolescents: 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Healthy adults: Urine (5%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323230\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Venofer Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $60.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184595\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anerrum (TH);</li>\n      <li>Avofer (MY);</li>\n      <li>Dialifer (ID);</li>\n      <li>Encifer (LK, ZW);</li>\n      <li>Femax (PH);</li>\n      <li>Femorum (TH);</li>\n      <li>Feofer (BD);</li>\n      <li>Ferogen (TH);</li>\n      <li>Feromax (ET, QA);</li>\n      <li>Feromin (PH);</li>\n      <li>Ferrofer (TH);</li>\n      <li>Ferrovin (KR);</li>\n      <li>Incros (LK);</li>\n      <li>Maxifer (PH);</li>\n      <li>Medofer (PH);</li>\n      <li>Nefrofer (BD, ID);</li>\n      <li>Rafofer (CL);</li>\n      <li>Rinofer (ID);</li>\n      <li>Sucrox (AR);</li>\n      <li>Venofer (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IS, JO, LB, LK, LT, LU, LV, MY, NI, NL, NO, NZ, PA, PE, PK, PL, PT, PY, RO, SE, SG, SI, SK, SV, TH, TR, UY, VE, ZA);</li>\n      <li>Venoferrum (KR);</li>\n      <li>Xenofer (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    al-Momen AK, al-Meshari A, al-Nuaim L, et al &quot;Intravenous Iron Sucrose Complex in the Treatment of Iron Deficiency Anemia During Pregnancy,&quot; <i>Eur J Obstet Gynecol Reprod Biol</i>, 1996, 69(2):121-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/8902444/pubmed\" target=\"_blank\" id=\"8902444\">8902444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2008, 112(1):201-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/18591330/pubmed\" target=\"_blank\" id=\"18591330\">18591330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Blumenthal S, et al, &quot;Iron Sucrose in Hemodialysis Patients: Safety of Replacement and Maintenance Regimens,&quot; <i>Kidney Int</i>, 2004, 66(3):1193-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/15327417/pubmed\" target=\"_blank\" id=\"15327417\">15327417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo; <i>Hematol Oncol Clin North Am</i>, 2000, 14(5):1061-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/11005034/pubmed\" target=\"_blank\" id=\"11005034\">11005034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18375890\"></a>Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. <i>J Clin Oncol</i>. 2008;26(10):1611-1618.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/18375890/pubmed\" target=\"_blank\" id=\"18375890\">18375890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17302514\"></a>Breymann C, von Seefried B, Stahel M, Geisser P, Canclini C. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex. <i>J Perinat Med</i>. 2007;35(2):115-118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/17302514/pubmed\" target=\"_blank\" id=\"17302514\">17302514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17252006\"></a>Hedenus M, Birgeg&aring;rd G, N&auml;sman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. <i>Leukemia</i>. 2007;21(4):627-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/17252006/pubmed\" target=\"_blank\" id=\"17252006\">17252006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease (2006). Available at: http://www2.kidney.org/professionals/KDOQI/guidelines_anemia/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Available at: http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leijn E, Monnens LA, and Cornelissen EA, &ldquo;Intravenous Iron Supplementation in Children on Hemodialysis,&rdquo; <i>J Nephrol</i>, 2004, 17(3):423-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/15365964/pubmed\" target=\"_blank\" id=\"15365964\">15365964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacKay M, Rusho W, Jackson D, et al, &quot;Physical and Chemical Stability of Iron Sucrose in Parenteral Nutrition,&quot; <i>Nutr Clin Pract</i>, 2009, 24(6):733-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/19955552/pubmed\" target=\"_blank\" id=\"19955552\">19955552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo; Am J Kidney Dis, 2007, 50(3):529-30. Available at http://www2.kidney.org/professionals/KDOQI/guidelines_anemiaUP/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Damme-Lombaerts R and Herman J, &ldquo;Erythropoietin Treatment In Children With Renal Failure,&rdquo; <i>Prediatr Nephrol</i>, 1999, 13(2):148-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iron-sucrose-drug-information/abstract-text/10229005/pubmed\" target=\"_blank\" id=\"10229005\">10229005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venofer (iron sucrose) [prescribing information]. Shirley, NY: American Regent Inc; November 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9004 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184604\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184605\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F184620\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F184607\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6010345\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F184608\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160034\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160035\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184587\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F184573\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963477\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F184590\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F184589\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474543\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7897706\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184579\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184593\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184577\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299545\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184581\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184583\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184594\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6789329\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F184585\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F184588\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184576\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F184592\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323230\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184595\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9004|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iron-sucrose-patient-drug-information\" class=\"drug drug_patient\">Iron sucrose: Patient drug information</a></li><li><a href=\"topic.htm?path=iron-sucrose-pediatric-drug-information\" class=\"drug drug_pediatric\">Iron sucrose: Pediatric drug information</a></li></ul></div></div>","javascript":null}